RxDoctor Payments Data

Pamela Rucki, MD

Family Medicine · Canal Fulton, OHNPI 1548246176

Payments from drug & device makers

$9,456in general payments, 2019–2025

Across 649 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$907
  • GSK$829
  • Pfizer$781
  • Novo Nordisk$753
  • Boehringer Ingelheim$566
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$9,37699%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,456 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$42,579
Medicare patients
136
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$114,272
JardianceEmpagliflozin61$70,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$54,963
XareltoRivaroxaban40$39,099
MounjaroTirzepatide13$34,287
Breo ElliptaFluticasone/Vilanterol40$21,558
FarxigaDapagliflozin Propanediol19$21,000
Soliqua 100-33Insulin Glargine/Lixisenatide16$19,819
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$19,501
MyrbetriqMirabegron24$16,692
OzempicSemaglutide12$13,350
JanumetSitagliptin Phos/Metformin Hcl26$11,750
JanuviaSitagliptin Phosphate16$11,595
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$7,969
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$6,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$781$114,272117 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$829$96,021109 claims
Boehringer IngelheimJardiance$566$70,93561 claims
Johnson & JohnsonXarelto$243$39,09940 claims
Lilly USA, LLCMounjaro$362$34,28713 claims
AstraZenecaFarxiga, Symbicort$907$26,41136 claims
MerckJanumet, Januvia$524$23,34442 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$146$19,81916 claims
Astellas Pharma US IncMyrbetriq$349$16,69224 claims
Novo NordiskOzempic$753$13,35012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Canal Fulton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →